Dyadic International, Inc. (NASDAQ:DYAI) Short Interest Up 74.5% in March

Dyadic International, Inc. (NASDAQ:DYAI) saw a large increase in short interest in March. As of March 31st, there was short interest totalling 167,900 shares, an increase of 74.5% from the March 15th total of 96,200 shares. Based on an average trading volume of 60,400 shares, the short-interest ratio is currently 2.8 days. Currently, 0.8% of the company’s stock are sold short.

Dyadic International Trading Down 0.8 %

NASDAQ DYAI opened at $1.23 on Friday. The company’s 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $1.43. The company has a debt-to-equity ratio of 1.54, a quick ratio of 5.15 and a current ratio of 5.15. The company has a market capitalization of $37.01 million, a price-to-earnings ratio of -5.35 and a beta of 0.98. Dyadic International has a one year low of $0.93 and a one year high of $2.67.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The firm had revenue of $0.82 million for the quarter, compared to analysts’ expectations of $1.60 million. During the same period in the previous year, the company posted ($0.24) earnings per share. Equities analysts forecast that Dyadic International will post -0.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Two Sigma Securities LLC purchased a new stake in shares of Dyadic International during the fourth quarter worth about $25,000. Millennium Management LLC purchased a new position in shares of Dyadic International in the fourth quarter worth $28,000. Jane Street Group LLC acquired a new stake in shares of Dyadic International during the fourth quarter worth $45,000. Bank of America Corp DE increased its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 26,965 shares during the period. Finally, Inlet Private Wealth LLC purchased a new position in Dyadic International in the 4th quarter worth $52,000. 27.95% of the stock is owned by institutional investors and hedge funds.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.